Aims: The intermittent administration of chemotherapy is a means of preserving patients’ quality of life (QL). The aim of this study was to verify whether the intermittent administration of docetaxel (DOC) improves the patients’ QL. Patients & methods: All patients received DOC 70 mg/m² every 3 weeks for eight cycles. The patients were randomized to receive DOC continuously or with a fixed 3-month interval after the first four DOC courses. Results: The study involved 148 patients. There was no difference in QL between the groups receiving intermittent or continuous treatment. Intermittence had no detrimental effects on disease control. Conclusion: Although feasible and not detrimental, our results showed that true intermittent chemotherapy in metastatic castration-resistant prostate cancer patients failed to improve the patients’ QL.

Keywords:

Papers of special note have been highlighted as: • of interest; •• of considerable interest

References

1 Tannock IF, de Wit R, Berry WR et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N. Engl. J. Med. 351(15), 1502–1512 (2004).• Pivotal trial leading to docetaxel approval as first-line treatment in metastatic castration-resistant prostate cancer.
Medline CASGoogle Scholar
2 Petrylak DP, Tangen CM, Hussain MH et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N. Engl. J. Med. 351(15), 1513–1520 (2004).• Pivotal trial leading to docetaxel approval as first-line treatment in metastatic castration-resistant prostate cancer.
Medline CASGoogle Scholar
3 Pond GR, Armstrong AJ, Wood BA et al. Evaluating the value of number of cycles of docetaxel and prednisone in men with metastatic castration-resistant prostate cancer. Eur. Urol. 61(2), 363–369 (2012).
Medline CASGoogle Scholar
4 Berry DL, Moinpour CM, Jiang CS et al. Quality of life and pain in advanced stage prostate cancer: results of a Southwest Oncology Group randomized trial comparing docetaxel and estramustine to mitoxantrone and prednisone. J. Clin. Oncol. 24(18), 2828–2835 (2006).• Study reporting the quality of life impact of docetaxel-based chemotherapy on prostate cancer patients quality of life in a large Phase III trial.
Medline CASGoogle Scholar
5 Caffo O, Sava T, Comploj E et al. Impact of docetaxel-based chemotherapy on quality of life of patients with castration-resistant prostate cancer: results from a prospective phase II randomized trial. BJU Int. 108(11), 1825–1832 (2011).• Study reporting the quality of life impact of docetaxel-based chemotherapy on prostate cancer patients quality of life in a Phase II trial.
Medline CASGoogle Scholar
6 Tormey DC, Weinberg VE, Leone LA et al. A comparison of intermittent vs. continuous and of adriamycin vs. methotrexate 5-drug chemotherapy for advanced breast cancer. A Cancer and Leukemia Group B study. Am. J. Clin. Oncol. 7(3), 231–239 (1984).
Medline CASGoogle Scholar
7 Coates A, Gebski V, Bishop JF et al. Improving the quality of life during chemotherapy for advanced breast cancer. A comparison of intermittent and continuous treatment strategies. N. Engl. J. Med. 317(24), 1490–1495 (1987).
Medline CASGoogle Scholar
8 Muss HB, Case LD, Richards F et al. Interrupted versus continuous chemotherapy in patients with metastatic breast cancer. The Piedmont Oncology Association. N. Engl. J. Med. 325(19), 1342–1348 (1991).
Medline CASGoogle Scholar
9 Epirubicin-based chemotherapy in metastatic breast cancer patients: role of dose-intensity and duration of treatment. J. Clin. Oncol. 18(17), 3115–3124 (2000).
MedlineGoogle Scholar
10 Maughan TS, James RD, Kerr DJ et al. Comparison of intermittent and continuous palliative chemotherapy for advanced colorectal cancer: a multicentre randomised trial. Lancet 361(9356), 457–464 (2003).
Medline CASGoogle Scholar
11 Tournigand C, Cervantes A, Figer A et al. OPTIMOX1: a randomized study of FOLFOX4 or FOLFOX7 with oxaliplatin in a stop-and-go fashion in advanced colorectal cancer – a GERCOR study. J. Clin. Oncol. 24(3), 394–400 (2006).
Medline CASGoogle Scholar
12 Chibaudel B, Maindrault-Goebel F, Lledo G et al. Can chemotherapy be discontinued in unresectable metastatic colorectal cancer? The GERCOR OPTIMOX2 study. J. Clin. Oncol. 27(34), 5727–5733 (2009).
Medline CASGoogle Scholar
13 Adams RA, Meade AM, Seymour MT et al. Intermittent versus continuous oxaliplatin and fluoropyrimidine combination chemotherapy for first-line treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial. Lancet Oncol. 12(7), 642–653 (2011).
Medline CASGoogle Scholar
14 Eymard JC, Oudard S, Gravis G et al. Docetaxel reintroduction in patients with metastatic castration-resistant docetaxel-sensitive prostate cancer: a retrospective multicentre study. BJU Int. 106, 974–978 (2010).
Medline CASGoogle Scholar
15 Loriot Y, Massard C, Gross-Goupil M et al. The interval from the last cycle of docetaxel-based chemotherapy to progression is associated with the efficacy of subsequent docetaxel in patients with prostate cancer. Eur. J. Cancer 46(10), 1770–1772 (2010).
Medline CASGoogle Scholar
16 Di Lorenzo G, Buonerba C, Faiella A et al. Phase II study of docetaxel re-treatment in docetaxel-pretreated castration-resistant prostate cancer. BJU. Int. 107(2), 234–239 (2011).
Medline CASGoogle Scholar
17 Caffo O, Pappagallo G, Brugnara S et al. Multiple rechallenges for castration-resistant prostate cancer patients responding to first-line docetaxel: assessment of clinical outcomes and predictive factors. Urology 79(3), 644–649 (2012).
MedlineGoogle Scholar
18 Scher HI, Halabi S, Tannock I et al. Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. J. Clin. Oncol. 26(7), 1148–1159 (2008).
MedlineGoogle Scholar
19 Caffo O, Sava T, Comploj E et al. Docetaxel, with or without estramustine phosphate, as first-line chemotherapy for hormone-refractory prostate cancer: results of a multicentre, randomised phase II trial. BJU Int. 102(9), 1080–1085 (2008).
Medline CASGoogle Scholar
20 Aaronson NK, Ahmedzai S, Bergman B et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J. Natl. Cancer Inst. 85(5), 365–376 (1993).
Medline CASGoogle Scholar
21 Fayers P, Weeden S, Curran D; on behalf of the EORTC Quality of Life Study Group. EORTC QLQ-C30 Reference Values. EORTC, Brussels, Belgium (1998).
Google Scholar
22 Caraceni A, Mendoza TR, Mencaglia E et al. A validation study of an Italian version of the Brief Pain Inventory (Breve Questionario per la Valutazione del Dolore). Pain 65(1), 87–92 (1996).
Medline CASGoogle Scholar
23 Tannock IF, Osoba D, Stockler MR et al. Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points. J. Clin. Oncol 14(6), 1756–1764 (1996).
Medline CASGoogle Scholar
24 Cohen J. Statistical Power Analysis for the Behavioral Sciences. Academic Press, NJ, USA (1988).
Google Scholar
25 Sloan J, Symonds T, Vargas-Chanes D, Fridley B. Practical guidelines for assessing the clinical significance of health-related quality of life changes within clinical trials. Drug Inf. J. 37, 23–31 (2003).
Google Scholar
26 Farrar JT, Young JP, Jr, LaMoreaux L, Werth JL, Poole RM. Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale. Pain 94(2), 149–158 (2001).
Medline CASGoogle Scholar
27 Hussain M, Tangen CM, Berry DL et al. Intermittent versus continuous androgen deprivation in prostate cancer. N. Engl. J. Med. 368(14), 1314–1325 (2013).
Medline CASGoogle Scholar
28 Beer TM, Ryan CW, Venner PM et al. Intermittent chemotherapy in patients with metastatic androgen-independent prostate cancer: results from ASCENT, a double-blinded, randomized comparison of high-dose calcitriol plus docetaxel with placebo plus docetaxel. Cancer 112(2), 326–330 (2008).
Medline CASGoogle Scholar
29 Lin AM, Ryan CJ, Small EJ. Intermittent chemotherapy for metastatic hormone refractory prostate cancer. Crit. Rev. Oncol. Hematol. 61(3), 243–254 (2007).•• Review on rationale and potential use of intermittent chemotherapy in prostate cancer.
MedlineGoogle Scholar
30 Dorff TB, Crawford ED. Management and challenges of corticosteroid therapy in men with metastatic castrate-resistant prostate cancer. Ann. Oncol. 24(1), 31–38 (2013).
Medline CASGoogle Scholar
31 Eymard JC, Priou F, Zannetti A et al. Randomized phase II study of docetaxel plus estramustine and single-agent docetaxel in patients with metastatic hormone-refractory prostate cancer. Ann. Oncol. 18(6), 1064–1070 (2007).
MedlineGoogle Scholar

Vol. 11, No. 6

Metrics

Downloaded 168 times

History

Published online 11 March 2015

Published in print March 2015

Information

Keywords

Financial & competing interests disclosure

U Basso received honoraria from Sanofi Aventis. O Caffo received honoraria from Sanofi Aventis and Janssen. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

No writing assistance was utilized in the production of this manuscript.

Ethical conduct of research

The authors state that they have obtained appropriate institutional review board approval or have followed the principles outlined in the Declaration of Helsinki for all human or animal experimental investigations. In addition, for investigations involving human subjects, informed consent has been obtained from the participants involved.

PDF download